Mechanisms and treatment of asthma, COPD (chronic obstructive lung disease), and other lung diseases
Understanding how disease occurs by studying basic mechanisms in experimental models and in patients who volunteer for research (asthma, COPD, lung disease, treatments for lung disease)
Gary P. Anderson, PhD
Gary Anderson is a pharmacologist and immunologist based in the Medical Faculty at the University of Melbourne, Australia, one of the world’s leading research-intensive Universities and Medical Schools (www.unimelb.edu.au) where he is a tenured Professor and Director of the Centre for Lung Health Research.
Gary’s own research has centred on using genetic disease models to understanding molecular mechanisms of disease induction, progression, severity and exacerbation in asthma and COPD. He co-discovered the role of Fas in lung inflammation, IL-4 in immune biasing in asthma models and the bronchoprotective PAR receptor system in the airway epithelium. Recent research has explored how blood growth factors control innate immunity in asthma and COPD; IL-17 in persistent inflammation; linking mutations in src-kinases to non-T cell determinants of very severe lung disease; plasticity and heterogeneity of lung macrophage progenitors; novel blood biomarkers in COPD exacerbations; molecular determinants of muscle wasting in COPD, GM-CSF as a therapeutic target; genetic reprogramming of lung stem cells and the molecular co-determinants of emphysema and lung cancer; and, the role of SAA in lung inflammation and allosteric block of catabasis. In 2008 he proposed the widely cited endotype (http://en.wikipedia.org/wiki/Endotype) concept of asthma (Lancet). He works closely with clinical colleagues in Melbourne’s preeminent Hospitals, especially the Departments of Respiratory Medicine and Clinical Immunology at the Royal Melbourne Hospital (www.rmh.mh.org.au ), on translational lung disease research. He is the author of more than 150 highly cited manuscripts on lung disease research and is a recipient of the Research Medal of the Thoracic Society of Australia and New Zealand (TSANZ) for his contribution to lung disease research.
Prior to returning in Australia Gary worked in the Swiss Pharmaceuticals Industry (Sandoz and